Schema


ComboMATCH REGISTRATION Trial
Standard of care genomic testing ordered at a Designated Lab (DL) by clinician
Physician identifies patient potentially eligible for Combo MATCH
Physician and patient choose Combo MATCH
Physician assesses brief Registration protocol eligibility
Patient consents to Registration trial
Site enrolls patient in OPEN with relevant clinical information
MATCHBox uses genomic data from DL and clinical data from OPEN as part of algorithm to assign ComboMATCH Treatment Trial
Treatment Trial assignment is provided to site
ComboMATCH TREATMENT Trials
Assess patient eligibility for Treatment Trial assignment
Patient consents to Treatment Trial and is enrolled in OPEN within 3 weeks of assignment
Treatment Trial
Liquid biopsies
Pre-treatment tumor biopsy (or recent archival tissue)
Post-progression tumor biopsy
Patient progresses
Patient can be assigned to a second Treatment Trial after progression if eligible

3. Selection of Patients

Each of the criteria in the checklist that follows must be met in order for a patient to be considered eligible for this study. Use the checklist to confirm a patient's eligibility. For each patient, this checklist must be photocopied, completed and maintained in the patient's medical chart/electronic health record.

ECOG-ACRIN Patient No. _____

Patient's Initials (L, F, M) _

Physician Signature and Date _____

NOTE: CTEP Policy does not allow for the issuance of waivers to any protocol specified criteria (http://ctep.cancer.gov/protocolDevelopment/policies_deviations.htm). Therefore, all eligibility criteria listed in Section 3 must be met, without exception. The registration of individuals who do not meet all criteria listed in Section 3 can result in the participant being censored from the analysis of the study, and the citation of a major protocol violation during an audit, and require reporting to the CIRB as non-compliance.

All questions regarding clarification of eligibility criteria must be directed to the Group's Executive Officer (EA.ExecOfficer@jimmy.harvard.edu) or the Group's Regulatory Officer (EA.RegOfficer@jimmy.harvard.edu).

NOTE: Institutions may use the eligibility checklist as source documentation if it has been reviewed, signed, and dated prior to registration/randomization by the treating physician.

NOTE: Please refer to the Schema for details on the registration process.

NOTE: Current FDA, NCI, state, federal and institutional regulations concerning informed consent/assent will be followed.

3.1 Eligibility Criteria Screening

_____3.1.1 Patient must have measurable disease.

_____ 3.1.2 Patient must have an ECOG performance status between 0-2.

OR

_____ Patient must have Lansky performance status of ≥ 50% or Karnofsky performance status of ≥ 50%.

_____3.1.3 Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider.

_____3.1.4 All patients must have sequencing results available from an NCI credentialed Designated Laboratory (DL).

_____3.1.5 Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria:

- _____ Patients must have progressed on at least one line of standard systemic therapy.

OR

- Patients whose disease has no standard treatment that has been shown to prolong overall survival.

3.1.6 Patient must meet one of the following requirements:

a. Patients 18 years and older who have tumor amenable to minimal risk image-guided or direct vision biopsy and must be willing and able to undergo a tumor biopsy to obtain samples for research if the patient is to enroll in a ComboMATCH treatment trial.

OR

b. Patients 18 years and older who do not have disease that is biopsiable at minimal risk to the patient must confirm availability of an archival tumor tissue specimen for submission for research if the patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:

- Tissue must have been collected within 12 months prior to registration to the EAY191 Registration Trial
- Patient must not have had a RECIST response (CR or PR) to any intervening therapy after collection of the tissue
- Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available (see Section 5.3).

OR

c. Patients under 18 years old must confirm availability of an archival tumor tissue specimen for submission for research if patient enrolls to a ComboMATCH Treatment Trial. This tumor tissue must meet the following criteria:

- Formalin-fixed paraffin-embedded tumor tissue block(s) or slides must be available (see Section 5.3).

NOTE: **See specific ComboMATCH Treatment Trial protocol for tissue collection and management instructions.** Performance of the mandatory research biopsy or submission of pre-trial FFPE and collection and submission of the blood specimens for the integrated studies will be performed under the consent authority of the specific treatment trial protocol to which the patient is registered. No procedures to collect specimens for research only are to be performed for patients registered to the EAY191 Registration Trial only.

NOTE: Each ComboMATCH Treatment Trial contains specific eligibility criteria. If patient is found to not be eligible for the assigned ComboMATCH Treatment Trial, indication of ineligibility will trigger re-evaluation and potential assignment to another Treatment Trial.